Literature DB >> 7079345

Pancreatic glucagon and postprandial satiety in the rat.

N Geary, G P Smith.   

Abstract

The hypothesis that administration of pancreatic glucagon inhibits feeding by eliciting satiety for food was tested against several behavioral and physiological criteria of specificity. The effects of intraperitoneal glucagon injections on intake of a palatable milk diet were tested in rats maintained with ad lib access to pelleted diet. Injections of 25--800 micrograms/kg glucagon administered at meal onset inhibited meal size by 17--36%, but did not affect the normal postprandial behavioral satiety sequence or elicit any behavioral signs of toxicity. Latency to rest and intermeal interval were not affected. Glucagon decreased meal size by specifically inhibiting feeding during the terminal phase of the meal without affecting feeding earlier in the meal. This was also the case when glucagon was injected 4 min prior to meal onset. This range of glucagon doses did not affect water intake in water deprived rats consuming fluid volumes comparable to the milk intakes. They also did not affect body temperature. Finally, injection of 400 micrograms/kg glucagon after the initial exposure to a novel drinking fluid was not sufficient to form a conditioned taste aversion in a two bottle preference test. These data, together with reports that circulating pancreatic glucagon levels increase during meals, strongly suggest that pancreatic glucagon is involved in the production of postprandial satiety.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7079345     DOI: 10.1016/0031-9384(82)90081-6

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  15 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  [Regulation of food intake].

Authors:  W Langhans; E Scharrer
Journal:  Z Ernahrungswiss       Date:  1990-06

Review 3.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

4.  [Satiation mechanism].

Authors:  E Scharrer
Journal:  Z Ernahrungswiss       Date:  1984-12

Review 5.  Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity.

Authors:  Stephan J Guyenet; Michael W Schwartz
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

6.  Hypothalamic glucagon signaling inhibits hepatic glucose production.

Authors:  Patricia I Mighiu; Jessica T Y Yue; Beatrice M Filippi; Mona A Abraham; Madhu Chari; Carol K L Lam; Clair S Yang; Nikita R Christian; Maureen J Charron; Tony K T Lam
Journal:  Nat Med       Date:  2013-05-19       Impact factor: 53.440

Review 7.  Physiologic approaches to the control of obesity.

Authors:  M A Powers; T N Pappas
Journal:  Ann Surg       Date:  1989-03       Impact factor: 12.969

Review 8.  The incretin/glucagon system as a target for pharmacotherapy of obesity.

Authors:  Stefano Del Prato; Baptist Gallwitz; Jens Juul Holst; Juris J Meier
Journal:  Obes Rev       Date:  2021-10-28       Impact factor: 10.867

9.  Increased food intake with oxyntomodulin analogues.

Authors:  Samantha L Price; James S Minnion; Stephen R Bloom
Journal:  Peptides       Date:  2015-09-30       Impact factor: 3.750

10.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.